NGR TNF
Alternative Names: ARENEGYR; CNGRC peptide-TNF alpha conjugate; NGR-hTNF; NGR-TNFα; Tumour-homing-peptide-tumour-necrosis-factor-alpha-fusion-protein; Tumour-vasculature-targeted-tumour-necrosis-factor-alpha; ZafirideLatest Information Update: 07 Sep 2021
At a glance
- Originator Scientific Institute San Raffaele
- Developer AGC Biologics; European Organisation for Research and Treatment of Cancer; MolMed; Scientific Institute San Raffaele
- Class Antineoplastics; Recombinant fusion proteins
- Mechanism of Action Capillary permeability modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Mesothelioma
- Phase II Colorectal cancer; Liver cancer; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Small cell lung cancer
- No development reported Ovarian cancer; Soft tissue sarcoma; Solid tumours
Most Recent Events
- 07 Sep 2021 No development reported - Phase-II for Mesothelioma (First-line therapy) in Germany, Russia, Italy (IV)
- 07 Sep 2021 No development reported - Phase-II for Ovarian cancer (Combination therapy, Late-stage disease, Second-line therapy or greater) in United Kingdom, Italy (IV)
- 07 Sep 2021 No development reported - Phase-II for Soft tissue sarcoma (Combination therapy, Late-stage disease, Metastatic disease) in United Kingdom, France, Italy (IV)